Regeneron pharmaceuticals (regn) faces mounting pressure on sales, legal fronts – hagens berman

San francisco, feb. 21, 2025 (globe newswire) -- regeneron pharmaceuticals inc. (nasdaq: regn) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal challenges, and analyst downgrades. td cowen recently lowered its price target for regeneron to $1,030 from $1,230, citing increased competition and lower revenue estimates for eylea®, a key product.
REGN Ratings Summary
REGN Quant Ranking